Share

March 28, 2017; 88 (13) Article

Fast multiple sclerosis progression in North Africans

Both genetics and environment matter

Youssef Sidhom, Elisabeth Maillart, Sophie Tezenas du Montcel, Imen Kacem, Catherine Lubetzki, Riadh Gouider, Caroline Papeix
First published February 24, 2017, DOI: https://doi.org/10.1212/WNL.0000000000003762
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
230

Share

Article Information

vol. 88 no. 13 1218-1225
DOI: 
https://doi.org/10.1212/WNL.0000000000003762
PubMed: 
28235811
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received June 27, 2016
  • Accepted in final form December 29, 2016
  • First Published February 24, 2017.

Article Versions

Copyright & Usage: 
© 2017 American Academy of Neurology

Author Disclosures

    1. Youssef Sidhom, MD,
    2. Elisabeth Maillart, MD,
    3. Sophie Tezenas du Montcel, MD, PhD,
    4. Imen Kacem, MD,
    5. Catherine Lubetzki, MD, PhD,
    6. Riadh Gouider, MD and
    7. Caroline Papeix, MD, PhD
  1. Youssef Sidhom, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Elisabeth Maillart, MD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Biogen, funding for travel (2) Teva Pharmaceutical, funding for travel (3) Genzyme, funding for travel (4) Roche, funding for travel

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. (1): Teva Pharmaceuticals, lecture fees (2): Biogen, lecture fees (3): Novartis, lecture fees (4): Roche, lecture fees (5): Genzyme, lecture fees (6): Merck, lecture fees

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Sophie Tezenas du Montcel, MD, PhD,
    4. Scientific Advisory Boards:

    1. (1) Boston Scientific SAS

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. (1) Quantitative assessment of cerebellar impairments (EP14187649)

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Imen Kacem, MD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Catherine Lubetzki, MD, PhD,
    6. Scientific Advisory Boards:

    1. VERTEX , BIOGEN, NOVARTIS, GENZYME, ROCHE, VERTEX

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Associate editor BRAIN editorial board member of MSJ and MSJ and related disorders

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. BIOGEN, ROCHE, GENZYME

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. scientific collaboration with EMD SERONO

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Riadh Gouider, MD and
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Caroline Papeix, MD, PhD
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Novartis Biogen teva Roche

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (Y.S., E.M., C.L., C.P.) and Biostatistics Unit (S.T.d.M.), Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, France; Department of Neurology (Y.S., I.K., R.G.), UR12SP21, Razi Hospital; Faculty of Medicine of Tunis (Y.S., I.K., R.G.), University Tunis Elmanar, Tunisia; UMR_S1136 (S.T.d.M.) and UMR_S 1127 (C.L.), UPMC Univ Paris 06, Sorbonne Universités; and INSERM UMR_S 1136 (S.T.d.M.), Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.
  1. Correspondence to Dr. Sidhom: Youssef.sidhom{at}gmail.com
View Full Text

Article usage

Article usage: February 2017 to May 2022

AbstractFullPdfSource
Feb 201761009Highwire
Mar 201723632147Highwire
Apr 201710841225Highwire
May 20172911711Highwire
Jun 201710827Highwire
Jul 20175713Highwire
Aug 20176313Highwire
Sep 20175713Highwire
Oct 20173600Highwire
Nov 20176142Highwire
Dec 20172801Highwire
Jan 20184864Highwire
Feb 20183225Highwire
Mar 201856815Highwire
Apr 20184133Highwire
May 20184138Highwire
Jun 20186056Highwire
Jul 20185213Highwire
Aug 20182634Highwire
Sep 20184201Highwire
Oct 20186313Highwire
Nov 20186524Highwire
Dec 20184301Highwire
Jan 20193501Highwire
Feb 20193804Highwire
Mar 20192523Highwire
Apr 20193804Highwire
May 20192532Highwire
Jun 20193034Highwire
Jul 20192401Highwire
Aug 20191712Highwire
Sep 20191205Highwire
Oct 20192515Highwire
Nov 20193133Highwire
Dec 2019724Highwire
Jan 20202901Highwire
Feb 20201714Highwire
Mar 20201720Highwire
Apr 20202213Highwire
May 20202201Highwire
Jun 20202845Highwire
Jul 20201702Highwire
Aug 20203001Highwire
Sep 20201521Highwire
Oct 20202611Highwire
Nov 20202520Highwire
Dec 20202710Highwire
Jan 20211441Highwire
Feb 20211735Highwire
Mar 20212032Highwire
Apr 20212900Highwire
May 20211200Highwire
Jun 20212701Highwire
Jul 20213710Highwire
Aug 20212321Highwire
Sep 20211911Highwire
Oct 20214100Highwire
Nov 20215701Highwire
Dec 20213600Highwire
Jan 20221400Highwire
Feb 20222210Highwire
Mar 20223621Highwire
Apr 20222301Highwire
May 20222701Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

More Online

CME Course

Related Articles

Topics Discussed

Alert Me